Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome

Velarde, Gladys; Choudhary, Naila; Bravo‐Jaimes, Katia; Smotherman, Carmen; Sherazi, Saadia; Kraemer, Dale F.

doi:10.1016/j.numecd.2020.10.002

Cited by 12 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study conducted by Gladys P. Velarde et al, women with MetS were administered high-intensity atorvastatin for 3 months, and several markers were reviewed, such as lipogenesis, inflammation, and thrombogenesis [ 275 ]. Of note, women in the study were not affected by cardiovascular disease or diabetes and had minor 10 year ASCVD risk.…”

Section: Managementmentioning

confidence: 99%

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Fahed

Aoun

Zerdan

et al. 2022

IJMS

715

366

View full text Add to dashboard Cite

Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis of MetS encompasses multiple genetic and acquired entities that fall under the umbrella of insulin resistance and chronic low-grade inflammation. If left untreated, MetS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases (CVDs). Given that CVDs constitute by far the leading cause of morbidity and mortality worldwide, it has become essential to investigate the role played by MetS in this context to reduce the heavy burden of the disease. As such, and while MetS relatively constitutes a novel clinical entity, the extent of research about the disease has been exponentially growing in the past few decades. However, many aspects of this clinical entity are still not completely understood, and many questions remain unanswered to date. In this review, we provide a historical background and highlight the epidemiology of MetS. We also discuss the current and latest knowledge about the histopathology and pathophysiology of the disease. Finally, we summarize the most recent updates about the management and the prevention of this clinical syndrome.

show abstract

Section: Managementmentioning

confidence: 99%

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Fahed

Aoun

Zerdan

et al. 2022

IJMS

715

366

View full text Add to dashboard Cite

show abstract

“…Las concentraciones superiores a 15 ng/ml de leptina, fueron más frecuentes en los participantes que consumían atorvastatina; y aún más, en quienes consumían 20 mg/ día; sin embargo, no hubo diferencias significativas respecto a las concentraciones de leptina, frente al régimen de estatina. Se han registrado pocos estudios en los que se relacionen los efectos de las estatinas y específicamente lovastatina y/o atorvastatina sobre las concentraciones séricas de leptina, en los estudios realizados por Bulcão C et al y Velarde G et al, se aportó evidencia en la cual se sugiere que no se relaciona el nivel de leptina con la estatina administrada a los participantes 19,26 , pero en cambio se han descrito de manera amplia múltiples factores que se relacionan con la cantidad plasmática de leptina y que pudieron influir en estos resultados. Los participantes con promedios de IMC superior al valor normal de referencia, en su mayoría estaban consumiendo atorvastatina y quienes consumían 20 mg/día registraron los mayores promedios de IMC; lo que se ha descrito ampliamente como un factor correlacionado de manera directa con las concentraciones plasmáticas de leptina 27 .…”

Section: Discussionunclassified

“…Leptina y adiponectina se relacionan de manera estrecha con riesgo cardiovascular y síndrome metabólico; los pacientes con enfermedades cardiovasculares reciben en su terapéutica, algunos fármacos entre ellos las estatinas, cuyo objetivo terapéutico es el control de las dislipidemias, y al respecto; varios estudios han sugerido impacto o relación de estas con las concentraciones de adipoquinas; sin embargo, no es claro el mecanismo mediante el cual lo hacen y de manera adicional, existen resultados controversiales (19)(20)(21) . Por lo anterior, en este estudio se tuvo como objetivo general comparar las concentraciones de leptina y adiponectina, según el régimen de estatina que recibían los participantes al momento de la extracción de la muestra.…”

Section: Estatinasunclassified

Comparison of statins effects on serum concentrations of leptin and adiponectin

Cárdenas-Parra

Osório²

2022

Duazary

View full text Add to dashboard Cite

Los estudios que relacionan el efecto de las estatinas sobre los niveles de adipocitoquinas, han reportado controversias; por lo que, es necesario contribuir a dilucidar la relación entre estas. El objetivo fue comparar las concentraciones séricas de leptina y adiponectina, en pacientes crónicos, según el régimen de estatina instaurado. El presente estudio es de tipo observacional, transversal, de nivel relacional. Fueron tomados datos de historias clínicas de 76 participantes y se les cuantificó leptina y adiponectina en suero, mediante la técnica de ELISA tipo sándwich. El análisis relacional se realizó mediante las pruebas de U-Mann-Whitney y H-Kruskal-Wallis. Las concentraciones séricas de leptina fueron homogéneas e independientes del régimen de estatina suministrado; por el contrario, las de adiponectina, fueron menores en quienes consumían 40 mg/ día de atorvastatina. Atorvastatina a 40 mg/día se relaciona con concentraciones plasmáticas de adiponectina inferiores, respecto a la adiponectinemia de los participantes manejados con otros regímenes de estatina. Para la comunidad científica es importante investigar sobre estos biomarcadores, para dilucidar relaciones que permitan predecir con mayor precisión el impacto, especialmente de atorvastatina a dosis intermedia y alta, como fármaco con mayores beneficios frente a eventos cardiovasculares y síndrome metabólico.

show abstract

“…Fibrates are also effective in hyperlipidemia, especially in the control of atherosclerotic dyslipidemia ( 128 ). In addition, the anti-inflammatory, antioxidant, antithrombotic, anti-fibrotic, and endothelial cell function improvement effects of statins can reduce proteinuria in patients with MetS and delay the progression of kidney disease ( 129 ). A study found that the benefit of cardiovascular protection in patients with MetS treated with statins was significantly higher than that without MetS.…”

Section: Management Of Mets-related Kidney Diseasementioning

confidence: 99%

Metabolic Syndrome-Related Kidney Injury: A Review and Update

Tan

Pan

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Metabolic syndrome (MetS) includes visceral obesity, hyperglycemia, dyslipidemia, and hypertension. The prevalence of MetS is 20-25%, which is an important risk factor for chronic kidney disease (CKD). MetS causes effects on renal pathophysiology, including glomerular hyperfiltration, RAAS, microalbuminuria, profibrotic factors and podocyte injury. This review compares several criteria of MetS and analyzes their differences. MetS and the pathogenesis of CKD includes insulin resistance, obesity, dyslipidemia, inflammation, oxidative stress, and endothelial dysfunction. The intervention of MetS-related renal damage is the focus of this article and includes controlling body weight, hypertension, hyperglycemia, and hyperlipidemia, requiring all components to meet the criteria. In addition, interventions such as endoplasmic reticulum stress, oxidative stress, gut microbiota, body metabolism, appetite inhibition, podocyte apoptosis, and mesenchymal stem cells are reviewed.

show abstract

Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome

Cited by 12 publications

References 33 publications

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Comparison of statins effects on serum concentrations of leptin and adiponectin

Metabolic Syndrome-Related Kidney Injury: A Review and Update

Contact Info

Product

Resources

About